**ABSTRACT AUTHORS**

**Contact Information**

|  |  |  |  |
| --- | --- | --- | --- |
| **LAST NAME** | **FIRST NAME** | **TITLE** | **EMAIL** |
| ADILI | ALI | IL-10 IN TRIPLE NEGATIVE METASTATIC BREAST CANCER | ALI.ADILI@MOFFITT.ORG |
| AGGARWAL | VAISHALI | INTERFERON-Γ, A MASTER REGULATOR DRIVING IMMUNE RESPONSE AND T-CELL EXHAUSTION | VAA30@PITT.EDU |
| AHMED | AML | STUDY OF PI3K ONCOGENE ADDICTION IN NON-SMALL CELL LUNG CANCER (NSCLC) | AAHMED6@MDANDERSON.ORG |
| BHATIA | ISHAN | HELPING TO DEVELOP NOVEL CAR-T CELL THERAPY FOR PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA IN INDIA | IIBHATIA97@GMAIL.COM |
| CHAKRABORTY | SRIJA | ENHANCING NATURAL KILLER CELL HOMING TO MELANOMA ORGANOIDS IN A TUMOR-ON-A-CHIP PLATFORM VIA INDUCTION OF TUMOR-CELL SECRETED CHEMOKINES | CHAKRABORTY.117@BUCKEYEMAIL.OSU.EDU |
| CHEN | YU-HIS | TITERING CAR EXPRESSION ON PRIMARY T CELLS ENABLED BY MICROFLUIDIC BASED DOSAGE CONTROLLED INTRACELLULAR DELIVERY PLATFORM | YUHSIC6@UCI.EDU |
| CHOUKRANI | GHIZLANE | GALECTIN-9 SHIFTS THE PHAGOCYTIC BALANCE ON CANCER CELLS AND TRIGGERS NEUTROPHIL-MEDIATED ANTICANCER IMMUNITY. | GHIZLANCHOUKRANI@GMAIL.COM |
| CHUKWUKERE | CHINAZAEKPERE | IMMUNOTHERAPY - PINEAPPLE, AND COLOSTRUM FROM BREASTMILK CAN BE THE MISSING PUZZLE IN DEFINITE CANCER TREATMENT. | NAZYCHUKS01@GMAIL.COM |
| DAR | MUKHTAR AHMAD | DESIGNING OF PEPTIDE BASED MULTI-EPITOPE VACCINE CONSTRUCT AGAINST GALLBLADDER CANCER USINGIMMUNOINFORMATICS AND COMPUTATIONAL APPROACHES | DARMUKTHAR55@GMAIL.COM |
| GUNTURI | ALEKHYA | CHARACTERIZATION OF NOVEL ANTI-TIGIT ANTIBODIES FOR POTENTIAL ANTI-TUMOR ACTIVITY | AGUNTURI@BU.EDU |
| HAGAR | AMIT | AN INTEGRATED VIRTUAL TISSUE PLATFORM FOR INCORPORATING EXERCISE ONCOLOGY INTO IMMUNOTHERAPY  | AMITHAGAR@GMAIL.COM |
| HUANG | YUE | MESOPOROUS SILICA NANOPARTICLES AS ROS SENSITIVE CARRIER FOR THERAVAC REGIMEN ENHANCE THE LOCAL IMMUNE RESPONSE IN MICE | YUE.HUANG@NIH.GOV |
| JALBUENA | AMANGELIN | DEFINING T-CELL RESPONSES TO MUTANT AND NON-MUTANT ANTIGENS IN MOUSE MELANOMA DURING ANTI-CTLA-4 IMMUNE CHECKPOINT THERAPY | ADJALBUENA@GMAIL.COM |
| KARALIOTA | SEVASTI | HETERODIMERIC IL-15 (HETIL-15) IMMUNOTHERAPY REVERSES CD8+T CELL METABOLIC DYSFUNCTION IN MURINE BREAST TUMORS | SEVASTI.KARALIOTA@NIH.GOV |
| KNIGHT | JULIA | ALDH INHIBITION AS MODULATOR OF OVARIAN TUMOR ASSOCIATED MACROPHAGES | JCK81@PITT.EDU |
| KONDURI | VANAJA | DENDRITIC CELL GOVERNANCE OF AN INNATE-LIKE CYTOTOXIC EFFECTOR MEMORYCD8+CD161+ T CELL SUBSET | KONDURI@BCM.EDU |
| LEYFMAN | YAN | IMPROVING HEALTHCARE ACCESS THROUGH THE DEVELOPMENT OF AN ONTOLOGY PLATFORM TO CONNECT BALT PATIENTS INFECTED WITH COVID-19 TO IMMUNOTHERAPEUTIC CLINICAL TRIALS | YANLEYFMAN7@GMAIL.COM |
| LIU | WENLONG | ANTI-MESOTHELIN IMMUNOTOXIN LMB-100 INDUCES COMPLETE TUMOR REGRESSIONS OF PERITONEAL MESOTHELIOMA, ANTI-TUMOR IMMUNITY AND THE DEVELOPMENT OF TERTIARY LYMPHOID STRUCTURE (TLS) | LIUW11@NIH.GOV |
| MAJUMDAR | SHUBHABRATA | FINE-TUNING CHIMERIC ANTIGEN RECEPTOR SIGNALING BY REDUCING CD3Ζ ITAM DIVERSITY | SHUBHABRATA92@GMAIL.COM |
| MARLIN ANDREWS | CELINE | HARNESSING THE INNATE IMMUNE RESPONSE FOR POTENTIAL MALIGNANT MELANOMA THERAPY | CMANDREWS@VT.EDU |
| MARTIN | SUNIL | EXPANSION AND TRANSDUCTION OF HUMAN Γ9Δ2 T CELLS TO TARGETHEMATOLOGIC MALIGNANCIES | SUNILMARTIN03@GMAIL.COM |
| MASTROPAOLO | MARIA | PATIENT-DERIVED ORGANOIDS MODEL SENSITIVITY AND RESISTANCE TO PARP INHIBITORS IN PATIENTS WITH METASTATIC COLORECTAL CANCER | MARIAMASTRO143@GMAIL.COM |
| MHIBIK | MAISSA | TREATMENT WITH BTK INHIBITOR OR BCL-2 INHIBITOR ENHANCES CYTOTOXICITY OF THE ANTI-CD3XCD20 BISPECIFIC ANTIBODY EPCORITAMAB AGAINST CHRONIC LYMPHOCYTIC LEUKEMIA | MAISSA.MHIBIK@NIH.GOV |
| MOHANTY | AYUSHI | COMBINED DRUG EFFICACY IN PRECLINICAL MODELS OF COLORECTAL CANCER | 2AYUSHIM@GMAIL.COM |
| MOORE | EMILY | CHARTING THE TUMOR-REACTIVE T CELL REPERTOIRE IN DNA DAMAGE REPAIR (DDR) DEFICIENT PANCREATIC CANCER TOWARDS PERSONALIZED T-CELL THERAPY | EKM2150@CUMC.COLUMBIA.EDU |
| MUELLER | JUERGEN | DELETION OF NK CELLS AND RE-DIRECTING OF DENDRITIC CELL DIFFERENTIATION DURING T LYMPHOMA DEVELOPMENT IN MICE | MUELLERJ@MAIL.NIH.GOV |
| NAHAR | SAIFUN  | EFFECTIVE IMMUNOTHERAPEUTIC REGIMEN WITH COMBINATIONS OF TLR AGONISTS AND IMMUNE CHECK POINTBLOCKADE AGAINST MOUSE 4T1 BREAST CARCINOMA | NAHARS2@NIH.GOV |
| NCEMBU | SIKOZILE | RECOMBINANT CD-64 DIRECTED SINGLE-CHAIN ANTIBODY FUSION PROTEIN EXHIBITS CYTOTOXICITY AND IS A TOOL FOR SITE-SPECIFIC DIAGNOSIS OF ACUTE MYELOID LEUKEMIA | SIKOZILENCEMBU@GMAIL.COM |
| NISAR | ALBEENA | IMPLEMENTING FAST TRACK COST EFFECTIVE PROCESS DEVELOPMENTAL STRATEGIES AND QUALITY BY DESIGN APPROACH FOR SUCCESSFUL TRANSITION OF CELL BASED IMMUNOTHERAPEUTIC PRODUCTS INTO CLINICS - THE EXPERIENCE FROM THE FIRST CAR T & CELL THERAPY CENTRE IN INDIA | NISARALBEENA15@GMAIL.COM |
| ONDA | MASANORI | 15B6 CAR T CELLS THAT BIND TO A JUXTAMEMBRANE REGION OF MESOTHELIN AND ARE NOT BLOCKED BY SHED MESOTHELIN | ONDAM@MAIL.NIH.GOV |
| OUCHEN | KHAOULA | OPTIMIZED LENTIVIRAL VECTOR DESIGN FOR ON-COMMAND GENE-CARGO DELIVERY BY ENGINEERED T CELLS | OUCHENKHAOULA1@GMAIL.COM |
| PATKAR | SUSHANT | TUMOR MICROENVIRONMENT (TME) LANDSCAPE DICTATES METASTATIC PROGRESSION AND TREATMENT SENSITIVITY OF CANINE AND HUMAN OSTEOSARCOMAS | PATKAR.SUSHANT@NIH.GOV |
| PRITAM | MANISHA | DEVELOPMENT OF LAG3 IMMUNE CHECKPOINT INHIBITORS FOR CANCER TREATMENT BY USING BIOINFORMATICS APPROACHES | MANISHA.PRITAM@NIH.GOV |
| SANYAL | SREYA | IMMUNOLOGICAL FEATURES AFFECTING GASTRIC TUMOR SENSITIVITY TO PD-1/PD-L1 INHIBITORS | SREYASCIENCE@GMAIL.COM |
| SMITH-UFFEN | MEGAN | ESTIMATING SCENARIOS FOR SURVIVAL TIME IN PATIENTS WITH METASTATIC MELANOMA RECEIVING IMMUNOTHERAPY OR TARGETED THERAPY | SMITHUFFEN.M@GMAIL.COM |
| SMITH-UFFEN | MEGAN | IMMUNE CHECKPOINT INHIBITOR-INDUCED POLYARTHRITIS: A CASE SERIES | SMITHUFFEN.M@GMAIL.COM |
| STRAVOKEFALOU | VASILIKI | REDUCTION OF CIRCULATING TUMOR CELLS AND METASTASIS FORMATION BY HETERODIMERIC IL-15 (HETIL-15) IMPROVES CHEMOTHERAPY AND SURGERY OUTCOME | VASILIKI.STRAVOKEFALOU@NIH.GOV |
| UGUZOVA | SABINE | PREDICTIVE VALUE OF CT SCANS AT 3 AND 6 MONTHS ON OVERALL SURVIVAL IN PATIENTS WITH METASTATIC RENAL CANCER ON 2ND AND LATER LINE NIVOLUMAB | UGUZOVA.SABINE@GMAIL.COM |
| VIGANT | FREDERIC | IN VIVO GENERATION OF TUMOR-METABOLISM-REGULATED HER-2-SPECIFIC CAR+ CELLS ERADICATE ESTABLISHED HER2+ GASTRIC CARCINOMAS WITH THE NOVEL SUBCUTANEOUS ROUTE OF ADMINISTRATION OF CD3-DIRECTED LENTIVECTOR-LOADED LYMPHOCYTES | FVIGANT@EXUMABIO.COM |
| VOYNOVA | ELISAVETA | INCREASED ACTIVITY OF A NK-SPECIFIC CAR-NK FRAMEWORK TARGETING CD3 AND CD5 FOR T-CELL LEUKEMIAS | ELISAVETA.VOYNOVA@NIH.GOV |
| WANG | BINBIN | DECOUPLING CYTOTOXIC T LYMPHOCYTE AND EXHAUSTED T LYMPHOCYTE TRANSCRIPTOMICSIGNATURES ENHANCES IMMUNE CHECKPOINT INHIBITORS RESPONSE PREDICTION IN MELANOMA | BINBIN.WANG@NIH.GOV |
| WARD | ROSS | INFLAMMASONE ACTIVATING NANOPARTICLES PROMOTE PROTECTIVE ANTI-TUMOUR CD8+ T CELLS | WARDRO@TCD.IE |
| YOSHIMOTO | SHO | PD-1CD28 SWITCH RECEPTOR OVERCOMES PD-L1 MEDIATED INHIBITION OF CANINE CAR-T CELLS | YSHO@VET.UPENN.EDU |
| ZENS | STEFAN | CHARTING THE TUMOR-REACTIVE T CELL REPERTOIRE IN DNA DAMAGE REPAIR (DDR) DEFICIENT PANCREATIC CANCER TOWARDS PERSONALIZED T-CELL THERAPY | S.ZENS@DKFZ-HEIDELBERG.DE |